Grant Krafft is a co-founder of Acumen and currently serves as Chief Scienctifc Advisor and Chairman of the Board of Directors. He is responsible for Acumen's research and development programs and scientific strategies, and he is the author and co-inventor of Acumen's patent portfolio.

Prior to Acumen, Dr. Krafft was Research Professor of Molecular Pharmacology and Biological Chemistry at Northwestern University Medical School, where he and his colleagues discovered Amyloid-b
Derived Diffusible Ligands (ADDLs).  Dr. Krafft also served as Director of Research Development for the ENH Research Institute, a Northwestern University Medical School affiliate.

Previously, Dr. Krafft held the positions of Chief Technical Officer of Tibotec-Virco, Belgium-based HIV therapeutics and pharmaco-genomics company, and was a scientific Volwiler Fellow at Abbott Laboratories in its Diagnostics and Pharmaceutical Products Divisions.

Dr. Krafft holds a B.S. in Chemistry from Valparaiso University, and a Ph.D. in Organic Chemistry from the University of Illinois, Urbana-Champaign. He also was an NIH post-doctoral fellow in the Chemistry Department at the University of Wisconsin, Madison.

Dr. Krafft is an author on more than 75 scientific papers and a co-inventor on more than 20 issued and pending patents. He has been the principal investigator on more than a dozen NIH, NSF, ACS and Alzheimer's Association grants and received an Alzheimer's Association T.L.L. Temple Award in 1999.